协同刺激分子B7-H1和B7-H3在乳腺癌的表达及临床意义  

Expressions and clinical significance of costimulatory molecules B7-H1 and B7-H3 in breast cancer

作　　者：高远[1] 刘彤[2] 孙静[2] 吴灵芝[1] 冯军[1] 殷红[1] 

机构地区：[1]苏州大学附属第一医院肿瘤科,江苏省215006 [2]苏州大学基础医学与生物科学学院免疫学系

出　　处：《江苏医药》2015年第23期2797-2799,F0002,共4页Jiangsu Medical Journal

基　　金：苏州市科技基金项目(SYS201464)

摘　　要：目的研究协同刺激分子B7同源体1(B7-H1)和B7-H3在乳腺癌组织中的表达及临床意义。方法采用免疫组织化学法检测59例乳腺癌组织及其相应癌旁正常组织中B7-H1、B7-H3表达,并分析其与临床特征的相关性。结果乳腺癌组织中B7-H1和B7-H3阳性表达率分别为47.46%和57.63%,均高于癌旁正常组织(P<0.05)。B7-H1表达与B7-H3表达呈正相关(r=0.917,P<0.01)。乳腺癌组织中B7-H1表达与人类表皮生长因子受体2(Her-2/neu)表达相关(P<0.05),与患者预后无明显相关(P>0.05);而B7-H3表达与患者肿瘤分期及预后均密切相关(P<0.05)。B7-H1/B7-H3双阳性患者5年中位生存率小于B7-H1/B7-H3双阴性患者(61.80%vs.90.10%)(P<0.05)。结论 B7-H1和B7-H3过表达在乳腺癌进展中发挥重要作用,对乳腺癌诊断及预后判断可能具有重要价值。Objective To investigate the expressions and clinical significance of costimulatory molecules B7‐homologue1 （B7‐H1 ） and B7‐H3 in breast cancer .Methods B7‐H1 and B7‐H3 expressions were detected by immunohistochemistry in 59 cases of breast cancer and its corresponding tumor‐adjacent normal tissues .Then the correlation between the expressions and clinicopathologic characteristics was analyzed .Results The positive expression rates of B7‐H1 and B7‐H3 in breast cancer were 47.46% and 57.63% ,which were higher than those in tumor‐adjacent normal tissues （P〈0 .05） .B7‐H1 expression was positively correlated with B7‐H3 expression in breast cancer （r=0 .917 ,P〈0 .01） .B7‐H1 expression was correlated with human epidermal growth factor receptor‐2（Her‐2/neu） expression（P〈0 .05） ,but was not relevant to the prognosis of patients with breast cancer （ P〉0 .05 ） .While B7‐H3 expression was correlated with tumor staging and prognosis （P〈0 .05） .The 5‐year survival rate of patients with positive expressions of B7‐H1 and B7‐H3 was lower than those with negative expressions of B7‐H1 and B7‐H3（61.8% vs .90.1% ）（P〈0 .05） . Conclusion Overexpressions of B7‐H1 and B7‐H3 are involved in the progression of breast cancer , which may play an important role in the diagnosis and prediction of the prognosis of patients with breast cancer .

关 键 词：乳腺癌 协同刺激分子 B7同源体 

分 类 号：R817[医药卫生—影像医学与核医学]